logo-loader
viewOncimmune

New US deal for Oncimmune on the back of mixed results

Oncimmune Holdings PLC (LON:ONC) has inked a new deal with US diagnostics firm Biodesix for its EarlyCDT lung cancer test. CEO Adam Hill tells Proactive London how significant the deal is and lays out his new three year strategic vision for the company, underlining a newly-implemented and strengthened cash position as well as an ability to drive growth through commercial collaborations.
The new deal will be worth up to US$28mln to Oncimmune over the next five years, with the agreement open for renewal for another five year period up to 2029.

Quick facts: Oncimmune

Price: 37 GBX

AIM:ONC
Market: AIM
Market Cap: £23.4 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Oncimmune named herein, including the promotion by the Company of Oncimmune in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: SIMEC Atlantis chosen for demo project in Japan

Headlines from the Proactive UK newsroom. SIMEC Atlantis Energy (LON:SAE) has been chosen to supply tidal generation equipment and offshore construction services for a demonstration project in Japan. The project is located in the straits of Naru Island.  Block Energy (LON:BLOE) has...

on 31/10/19

2 min read